TNFSF10 and prostate cancer: In prostate cancer, proteasome inhibitors also induced the up-regulation of TRAIL-R2 and sensitivity to TRAIL-induced apoptosis, suggesting that the combination of proteasome inhibitors and TRAIL is a novel therapeutic approach in treating TRAIL resistant tumors [92].